Patent application number | Description | Published |
20100179134 | PYRIMIDINEDIAMINE KINASE INHIBITORS - The present invention provides pyrimidinediamine compounds useful for inhibiting kinase activity, including the activity of polo-like kinase 1 (PLK1). Also provided are pharmaceutical compositions comprising these compounds and methods of treating diseases associated with kinase activity, in particular enhanced PLK1 catalytic activity, such as diseases associated with abnormal cell proliferation, including neoplastic disorders. | 07-15-2010 |
20100184755 | PROTEIN KINASE C INHIBITORS AND USES THEREOF - This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 07-22-2010 |
20100204208 | PROTEIN KINASE C INHIBITORS AND USES THEREOF - This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 08-12-2010 |
20130012501 | PYRIMIDINEDIAMINE KINASE INHIBITORS - Disclosed embodiments provide pyrimidinediamine compounds useful for inhibiting kinase activity, including the activity of polo-like kinase 1 (PLK1). Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating diseases associated with kinase activity, in particular enhanced PLK1 catalytic activity, such as diseases associated with abnormal cell proliferation, including neoplastic disorders. | 01-10-2013 |
20130143875 | Protein Kinase C Inhibitors and Uses Thereof - This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 06-06-2013 |
20130210810 | Protein Kinase C Inhibitors and Uses Thereof - This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 08-15-2013 |
20130309228 | PYRIMIDINEDIAMINE KINASE INHIBITORS - Disclosed embodiments provide pyrimidinediamine compounds useful for inhibiting kinase activity, including the activity of polo-like kinase 1 (PLK1). Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating diseases associated with kinase activity, in particular enhanced PLK1 catalytic activity, such as diseases associated with abnormal cell proliferation, including neoplastic disorders. | 11-21-2013 |
20150376203 | Protein Kinase C Inhibitors and Uses Thereof - This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 12-31-2015 |
Patent application number | Description | Published |
20110293496 | SYNTHESIS OF TRIAZOLE-BASED AND IMIDAZOLE-BASED ZINC CATALYSTS - Various methods and structures of complexes and molecules are described herein related to a zinc-centered catalyst for removing carbon dioxide from atmospheric or aqueous environments. According to one embodiment, a method for creating a tris(triazolyl)pentaerythritol molecule includes contacting a pentaerythritol molecule with a propargyl halide molecule to create a trialkyne molecule, and contacting the trialkyne molecule with an azide molecule to create the tris(triazolyl)pentaerythritol molecule. In another embodiment, a method for creating a tris(imidazolyl)pentaerythritol molecule includes alkylating an imidazole 2-carbaldehyde molecule to create a monoalkylated aldehyde molecule, reducing the monoalkylated aldehyde molecule to create an alcohol molecule, converting the alcohol molecule to create an alkyl halide molecule using thionyl halide, and reacting the alkyl halide molecule with a pentaerythritol molecule to create a tris(imidazolyl)pentaerythritol molecule. In another embodiment, zinc is bound to the tris(triazolyl)pentaerythritol molecule to create a zinc-centered tris(triazolyl)pentaerythritol catalyst for removing carbon dioxide from atmospheric or aqueous environments. | 12-01-2011 |
20120028372 | RAPID DETECTION AND IDENTIFICATION OF ENERGETIC MATERIALS WITH SURFACE ENHANCED RAMAN SPECTROMETRY (SERS) - In one embodiment, a system includes a plurality of metal nanoparticles functionalized with a plurality of organic molecules tethered thereto, wherein the plurality of organic molecules preferentially interact with one or more analytes when placed in proximity therewith. According to another embodiment, a method for detecting analytes includes contacting a fluid having one or more analytes of interest therein with a plurality of metal nanoparticles, each metal nanoparticle having a plurality of organic molecules tethered thereto, and detecting Raman scattering from an analyte of interest from the fluid, the analyte interacting with one or more of the plurality of organic molecules. In another embodiment, a method includes chemically modifying a plurality of cyclodextrin molecules at a primary hydroxyl moiety to create a chemical handle, and tethering the plurality of cyclodextrin molecules to a metal nanoparticle using the chemical handle. Other systems and methods for detecting analytes are also described. | 02-02-2012 |
20120199535 | TETHERED CATALYSTS FOR THE HYDRATION OF CARBON DIOXIDE - A system is provided that substantially increases the efficiency of CO | 08-09-2012 |
20140273250 | METHODS FOR THE SELECTIVE DETECTION OF ALKYNE-PRESENTING MOLECULES AND RELATED COMPOSITIONS AND SYSTEMS - Provided herein are methods for selectively detecting an alkyne-presenting molecule in a sample and related detection reagents, compositions, methods and systems. | 09-18-2014 |
20140273274 | METHODS FOR THE SELECTIVE DETECTION OF ALKYNE-PRESENTING MOLECULES AND RELATED COMPOSITIONS AND SYSTEMS - Provided herein are methods for selectively detecting an alkyne-presenting molecule in a sample and related detection reagents, compositions, methods and systems. | 09-18-2014 |
20140275432 | METHODS FOR THE SELECTIVE SEQUESTRATION OF ALKYNE-PRESENTING MOLECULES AND RELATED COMPOSITIONS AND METHODS - Provided herein are methods for sequestering an alkyne-presenting molecule in a sample and related sequestration reagents, compositions, methods and systems. | 09-18-2014 |
20150104367 | ACYCLIC AZA-CONTAINING LIGANDS FOR USE AS CATALYTIC CARBON CAPTURE SYSTEMS - According to one embodiment, a catalyst includes a metal ion, and an acyclic ligand having at least one aza-containing moiety, where the ligand is complexed to the metal ion. | 04-16-2015 |
20150192579 | RAPID DETECTION AND IDENTIFICATION OF ENERGETIC MATERIALS WITH SURFACE ENHANCED RAMAN SPECTROMETRY (SERS) - In one embodiment, a system includes a plurality of metal nanoparticles functionalized with a plurality of organic molecules tethered thereto, each organic molecule having a primary face and a secondary face. The plurality of organic molecules preferentially interact with the one or more analytes when placed in proximity therewith. The plurality of organic molecules comprise one or more of: one or more modifying groups on the primary face in place of one or more primary hydroxyl groups; and one or more modifying groups on the secondary face in place of one or more secondary hydroxyl groups. At least one of the one or more analytes is an energetic compound. In another embodiment, a method includes chemically modifying a plurality of cyclodextrin molecules at a primary hydroxyl moiety to create a chemical handle; and tethering the plurality of cyclodextrin molecules to a metal nanoparticle using the chemical handle. | 07-09-2015 |
Patent application number | Description | Published |
20090068719 | IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS - This invention provides compounds, methods, immunoassays, and kits relating to active, metabolically sensitive (“met-sensitive”) moieties of anti-HIV therapeutics, such as HIV protease inhibitors (PI) and HIV non-nucleoside reverse transcriptase inhibitors (NNRTI). | 03-12-2009 |
20090093069 | Topiramate Immunoassays - Diacetonefructose derivatives have substituents at the hydroxyl-position. Diacetonefructose derivatives may include immunogenic moieties to prepare anti-diacetonefructose derivative antibodies, or antigenic moieties for immunodiagnostic assays. Also, the diacetonefructose derivatives can include signal generating moieties for detecting the presence or amount of the diacetonefructose derivative in a sample. Additionally, the diacetonefructose derivatives can be used in immunodiagnostic assays to compete with topiramate for binding with anti-diacetonefructose derivative antibodies. Also, methods, compositions and kits are disclosed directed at diacetonefructose derivatives, immunogens, signal generating moieties and immunoassays for topiramate. | 04-09-2009 |
20140206020 | Voriconazole Immunoassays - Methods, compositions and kits are disclosed directed at voriconazole derivatives, immunogens, signal generating moieties, antibodies that bind voriconazole and immunoassays for detection of voriconazole. | 07-24-2014 |
Patent application number | Description | Published |
20080199887 | COMPOUNDS AND METHODS FOR USE IN DETECTING GABAPENTIN - Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays. | 08-21-2008 |
20100173427 | LEVETIRACETAM IMMUNOASSAYS - Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam. | 07-08-2010 |
20120190047 | Levetiracetam Immunoassays - Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam. | 07-26-2012 |
20150024456 | Compounds and Methods for Use in Detecting Gabapentin - Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays. | 01-22-2015 |
20150044693 | Levetiracetam Immunoassays - Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam. | 02-12-2015 |
Patent application number | Description | Published |
20130030520 | DELIVERY SYSTEMS FOR PROSTHETIC HEART VALVE - Described herein are systems and methods from delivering prosthetic devices, such as prosthetic heart valves, through the body and into the heart for implantation therein. The prosthetic devices delivered with the delivery systems disclosed herein are, for example, radially expandable from a radially compressed state mounted on the delivery system to a radially expanded state for implantation using an inflatable balloon of the delivery system. Exemplary delivery routes through the body and into the heart include transfemoral routes, transapical routes, and transaortic routes, among others. | 01-31-2013 |
20150342735 | DELIVERY SYSTEMS FOR PROSTHETIC HEART VALVE - Described herein are systems and methods from delivering prosthetic devices, such as prosthetic heart valves, through the body and into the heart for implantation therein. The prosthetic devices delivered with the delivery systems disclosed herein are, for example, radially expandable from a radially compressed state mounted on the delivery system to a radially expanded state for implantation using an inflatable balloon of the delivery system. Exemplary delivery routes through the body and into the heart include transfemoral routes, transapical routes, and transaortic routes, among others. | 12-03-2015 |
20160045309 | ARTIFICIAL HEART VALVE WITH SCALLOPED FRAME DESIGN - Implantable prosthetic valves are disclosed, methods of their use, and related fabrication techniques are disclosed. In some cases, the prosthetic valves disclosed herein can include frame, skirt, and valve components. The frame component can have an overall, generally scalloped shape comprising fewer struts and fabricated from less raw material than known frames. In some cases, the prosthetic valves disclosed herein can be crimped to a smaller diameter than can other known valves. | 02-18-2016 |
Patent application number | Description | Published |
20090013691 | PHASE CHANGE MATERIAL THERMAL POWER GENERATOR - An energy producing device, for example a submersible vehicle for descending or ascending to different depths within water or ocean, is disclosed. The vehicle comprises a temperature-responsive material to which a hydraulic fluid is associated. A pressurized storage compartment stores the fluid as soon as the temperature-responsive material changes density. The storage compartment is connected with a hydraulic motor, and a valve allows fluid passage from the storage compartment to the hydraulic motor. An energy storage component, e.g. a battery, is connected with the hydraulic motor and is charged by the hydraulic motor when the hydraulic fluid passes through the hydraulic motor. Upon passage in the hydraulic motor, the fluid is stored in a further storage compartment and is then sent back to the area of the temperature-responsive material. | 01-15-2009 |
20090214905 | Direct methanol fuel cell operable with neat methanol - A fuel cell system running on direct neat methanol. Back diffusion of water from the cathode to the anode is sufficiently high so that water is not accumulated at the cathode, thereby leading to fuel cell systems without the need for a pump system to remove circulate water from the cathode to the anode. Other embodiments are described and claimed. | 08-27-2009 |
20100089745 | IR-DOPED RUTHENIUM OXIDE CATALYST FOR OXYGEN EVOLUTION - A method for preparing a metal-doped ruthenium oxide material by heating a mixture of a doping metal and a source of ruthenium under an inert atmosphere. In some embodiments, the doping metal is in the form of iridium black or lead powder, and the source of ruthenium is a powdered ruthenium oxide. An iridium-doped or lead-doped ruthenium oxide material can perform as an oxygen evolution catalyst and can be fabricated into electrodes for electrolysis cells. | 04-15-2010 |
20110314811 | PHASE CHANGE MATERIAL THERMAL POWER GENERATOR - An energy producing device, for example a submersible vehicle for descending or ascending to different depths within water or ocean, is disclosed. The vehicle comprises a temperature-responsive material to which a hydraulic fluid is associated. A pressurized storage compartment stores the fluid as soon as the temperature-responsive material changes density. The storage compartment is connected with a hydraulic motor, and a valve allows fluid passage from the storage compartment to the hydraulic motor. An energy storage component, e.g. a battery, is connected with the hydraulic motor and is charged by the hydraulic motor when the hydraulic fluid passes through the hydraulic motor. Upon passage in the hydraulic motor, the fluid is stored in a further storage compartment and is then sent back to the area of the temperature-responsive material. | 12-29-2011 |
20140255807 | DIRECT METHANOL FUEL CELL OPERABLE WITH NEAT METHANOL - A fuel cell system running on direct neat methanol. Back diffusion of water from the cathode to the anode is sufficiently high so that water is not accumulated at the cathode, thereby leading to fuel cell systems without the need for a pump system to remove circulate water from the cathode to the anode. Other embodiments are described and claimed. | 09-11-2014 |